|Bid||108.73 x 3600|
|Ask||108.75 x 500|
|Day's Range||108.28 - 108.84|
|52 Week Range||92.65 - 110.51|
|PE Ratio (TTM)||8.22|
|Expense Ratio (net)||0.20%|
Given the strong performance of Opdivo, Bristol-Myers Squibb's Oncology segment emerged as its largest revenue contributor in 2016. The segment contributed ~35% of BMY's total revenue.
More than 250 exchange-traded funds launched last year, marking another banner year of new product introductions from the ETF industry. However, as is often par for the course with any year's new ETF launches, ...